GE HEALTHCARE LIMITED

Their core work

GE Healthcare Limited is the UK arm of a global medical technology company specialising in diagnostic imaging — PET and MRI scanners, radiopharmaceutical tracers, and the software that turns scan data into clinical evidence. Inside EU research consortia they contribute imaging platforms, amyloid PET tracers, and the industrial know-how needed to validate imaging biomarkers for regulatory use. They sit at the interface between academic neuroscience, pharma drug development, and hospital diagnostic practice, providing the scanner-and-tracer infrastructure on which multi-centre clinical studies depend. Their value in a consortium is access to deployed imaging technology and the regulatory experience to move a biomarker from research curiosity to approved diagnostic tool.

What they specialise in

How they've shifted over time

In 2016 their H2020 engagement opened with a concentrated bet on Alzheimer's disease — amyloid PET tracers, tracer delivery, and disease modelling in AMYPAD, followed quickly by real-world evidence and health-economics work in ROADMAP. From 2017 onward they broadened from a single-disease imaging focus into imaging biomarkers as a cross-therapeutic tool, with IB4SD-TRISTAN extending PET/MRI methods into lung disease, rheumatology and drug toxicology. The trajectory is clear: from "amyloid imaging for dementia" to "imaging biomarkers as a general-purpose instrument for drug development and safety".

They are moving from disease-specific imaging tools into platform-level imaging biomarkers usable across drug development pipelines — useful for anyone building consortia on translational imaging or regulatory-grade biomarker qualification.

How they like to work

GE Healthcare Limited joins H2020 consortia purely as an industrial partner — never as coordinator — typically within large IMI-style public-private partnerships that combine pharma, academia and imaging infrastructure providers. Across just three projects they have worked with 61 distinct organisations in 11 countries, indicating a hub-style network that rotates partners rather than repeating the same small circle. Partnering with them means plugging into a large, pharma-anchored consortium where they supply imaging hardware, tracers and regulatory experience rather than project management.

A broad European network — 61 consortium partners across 11 countries in just three projects — reflecting the large, pharma-led IMI consortia they participate in. Geographic reach is pan-European with a natural centre of gravity in UK/Western-European clinical imaging sites.

What sets them apart

Very few organisations in EU health consortia combine deployed clinical imaging hardware, proprietary PET tracers (including amyloid agents) and the regulatory track record to move imaging biomarkers toward approval — GE Healthcare Limited is one of them. Unlike academic imaging groups, they can deliver at scale and across hospital sites; unlike pure pharma partners, they own the scanner-and-tracer stack. That makes them the partner to approach when an imaging biomarker needs industrial validation rather than single-site proof of concept.

Highlights from their portfolio

• AMYPAD
  Flagship IMI project using amyloid PET imaging to change clinical management and prevention pathways in Alzheimer's disease — directly aligned with GE's own amyloid tracer portfolio.
• IB4SD-TRISTAN
  Long-running (2017-2024) translational imaging project extending PET/MRI biomarkers into drug-safety assessment across lung, rheumatology and toxicology — a cross-therapeutic platform play.
• ROADMAP
  Built a multimodal real-world-evidence platform for Alzheimer's, pairing imaging with health-economic and patient-outcome data — unusual scope for an imaging-hardware company.